Influence of infection related factors on neuropsychological performance of HIV seropositive subjects;Influencia de factores relacionados con la infección en el rendimiento neuropsicológico de seropositivos al VIH

Neurologia

Volumn 17, Issue 6, 2002, Pages 328-336

  Rodriguez Alvarez M ^a   Vazquez Justo E ^a  

^a UNIVERSITY OF SANTIAGO DE COMPOSTELA   (Spain)

Author keywords

AIDS; CD4; HIV infection; Neuropsychological assessment; Viral load

Indexed keywords

HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE DEFICIENCY; NEUROPSYCHOLOGICAL TEST; REVIEW; RISK FACTOR; VIRUS LOAD; COGNITIVE DEFECT; VIROLOGY;

ANTI-HIV AGENTS; COGNITION DISORDERS; ENGLISH ABSTRACT; HIV INFECTIONS; HUMAN; NEUROPSYCHOLOGICAL TESTS; RISK FACTORS; HUMANS;

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

EID: 0242597564     PISSN: 02134853     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (151)

1. Complicaciones de las infecciones por VIH y del SIDA sobre el sistema nervioso central y periférico
2. Neurological and neuropathological manifestations of HIV infection
3. Neurocognitive disorders in HIV-1 infection
4. Neurobehavioral aspects of HIV disease and AIDS: An update
5. Mild cognitive impairment and risk of mortality in HIV-1 infection
6. Neurologic signs and symptoms in a cohort of homosexual men followed for 4.5 years
7. Cognitive performance after progression to AIDS: A longitudinal study from the Multicenter AIDS Cohort Study
8. HIV infection and cognition in intravenous drug users: Long term follow up
9. Funcionamiento neuropsicológico en drogodependientes VIH/SIDA inmunodeprimidos: Importancia de las fase de la infección y del consumo de drogas
10. Verbal working memory in HIV-seropositive drug users
11. Assessment of cognitive function in asymptomatic HIV-positive
12. Cerebrospinal fluid human immunodeficiency virus type 1 RNA levels are elevated in neurocognitively impaired individuals with acquired immunodeficiency syndrome HIV Neurobehavioral Research Center Group
13. Plasma and cerebrospinal fluid human immunodeficiency virus type-1 (HIV-1) RNA levels in HIV-related cognitive impairment
14. Depression predicts procedural but not episodic memory in HIV-1 infection
15. Effects of depressed mood versus clinical depression on neuropsychological test performance among African American men impacted by HIV/AIDS
16. Cognitive risk factors and neuropsychological performance in HIV infection
17. Cognitive sequelae of repeated head injury in a population of intravenous drug users
18. Neuropsychological changes associated with psychiatric symptoms in HIV infected individuals without AIDS
19. Relationship between psychiatric disease and neuropsychological impairment in HIV seropositive individuals
20. Vulnerabilidad neuropsicológica de los drogodependientes a la infección por VIH-1
21. Low education as a possible risk factor for cognitive abnormalities in HIV-1: Findings from the multicenter AIDS cohort study (MACS)
22. Do asymptomatic HIV-seropositive individuals show cognitive deficit?
23. Neuropsychological studies of asymptomatic human immunodeficiency virus type-1 infected individuals
24. Neuropsychological abnormalities among HIV-infected individual in a community-based sample
25. Longitudinal neuropsychological evaluation of HIV infected intravenous drug users
26. The neuropsychological consequences of HIV infection in drug addicts
27. Neuropsychometric performance of asymptomatic HIV-infected subjects
28. Quantitative neurologic and neurobehavioral testing of persons infected with human immunodeficiency virus type 1
29. Neuropsychological and neurological function of human immunodeficiency virus seropositive asymptomatic individuals
30. HIV infection and drug use: Influence on cognitive function
31. Neuropsychological deficits in HIV-1 seropositive and seronegative intravenous drug users
32. Neuropsychological deficits in HIV-1 seropositive and seronegative intravenous drug users (IVDUs): A follow up study
33. Neurological and neuropsychological manifestations of HIV-1 infection: Association with AIDS-related complex but not asymptomatic HIV-1 infection
34. A follow-up study of neuropsychological function in asymptomatic HIV-infected patients
35. Neuropsychological assessment of HIV-seropositive haemophiliacs
36. Cognitive impairment in HIV infection
37. Impaired motor-skill learning, slowed reaction time, and elevated cerebrospinal fluid quinolinic acid in a subgroup of HIV-infected individuals
38. Three-year neuropsychological follow-up in a selected group of HIV-infected homosexual/bisexual men
39. Low prevalence of neurological and neuropsychological abnormalities in otherwise healthy HIV-1-infected individuals: Results from the Multicenter AIDS Cohort Study
40. Neuropsychological performance in HIV-1 infected homosexual men: The Multicenter AIDS Cohort Study (MACS)
41. Signs of cognitive change in HIV disease: An even-related brain potential study
42. Neuropsychological findings and psychiatric symptoms in HIV-1 infected and noninfected drug users
43. HIV-1 infection and intravenous drug use: Longitudinal neuropsychological evaluation of asymptomatic subjects
44. Development of a screening battery for HIV-related cognitive impairment: The MACS experience
45. Neuropsychological characterization of the AIDS dementia complex: A preliminary report
46. Neuropsychological deficit in haemaphiliacs with human immunodeficiency virus
47. Drug and alcohol use and neuropsychological performance in asymptomatic HIV infection
48. Change in neuropsychological performance in asymptomatic HIV infection: 1-year follow-up
49. Neuropsychological performance in symptomatic and asymptomatic HIV infection
50. Duration of illness and neuropsychological performance in asymptomatic HIV infection
51. Cognitive behavior in asymptomatic (CDC stage II and III) HIV-seropositive intravenous drug users
52. The correlations between neuropsychological and neuroanatomic changes over time in asymptomatic and symptomatic HIV-1-infected individuals
53. The HNRC 500-neuropsychology of HIV infection at different disease stages
54. A preliminary report on the neuropsychologic sequelae of human immunodeficiency virus
55. Early neuropsychological change in HIV infection
56. Decision-making speed in HIV-1 infection: A preliminary report
57. Abnormalities of visual spatial attention in HIV infection and the HIV-associated dementia complex
58. HIV-1 infection and nervous system abnormalities among a cohort of intravenous drug users
59. Cognitive abnormalities and disease progression in a selected population of asymptomatic HIV-positive subjects
60. Influence of cognitive reserve on neuropsychological functioning in asymptomatic human immunodeficiency virus-1 infection
61. Multidisciplinary baseline assessment of homosexual men with and without human imminodeficiency virus infecction
62. Neuropsychological abnormalities in AIDS and asymptomatic HIV seropositive patients
63. HIV-specific changes in the motor performance of HIV-positive intravenous drug abusers
64. Neuropsychological impairment among intravenous drug users in pre-AIDS stages of HIV infection
65. Early central nervous system response to HIV infection: Sleep distortion and cognitive-motor decrements
66. Cognition and immune function in HIV-1 infection
67. Neurocognitive effects of zidovudine and 2′, 3′-dideoxyinosine during the treatment of asymptomatic and symptomatic HIV-1 seropositive patients. Comparison with non-treated patients
68. Changes in neuropsychological performance of AIDS-related complex patients who progress to AIDS
69. Speed of memory scanning is not affected in early HIV-1 infection
70. Early signs of cognitive deficits among human immunodeficiency virus-positive hemophiliacs
71. Neuropsychiatric consequences of AIDS
72. Neuropsychological changes in a prospectively followed cohort of homosexual and bisexual men with and without HIV infection
73. Evidence of CNS impairment in HIV infection: Clinical, neuropsychological, EEG and MRI/MRS study
74. A prospective four year follow-up of neuropsychological function in HIV seropositive and seronegative methadone-maintained patients
75. Risk of human immunodeficiency virus type 1-related neurologic disease in a cohort of intravenous drug users
76. Neuropsychological changes in a prospectively followed cohort of intravenous drug users with and without HIV
77. A follow-up study of neuropsychological functioning in AIDS-patients. Pronostic significance and effect of zidovudine therapy
78. Characterizing the neuropsychological functioning of persons with human immunodeficiency virus (HIV) infection, part II. Neuropsychological functioning of persons at different stages of HIV infection
79. Neuropsychological performance in asymptomatic HIV infection
80. Evidence of early central nervous system involvement in the acquired immunodeficiency syndrome (AIDS) and other human immunodeficiency virus (HIV) infections
81. Marcadores serológicos e inmunológicos de la infección por VIH
82. CD4+ lymphocyte level and rate of decline as predictors of AIDS in intravenous drug users with HIV infection
83. Serological markers as prognostic criteria for the course HIV infection
84. Immunological, clinical and epidemiological, aspects of an HIV-1 positive drug abuser cohort
85. Immune activation markers and AIDS prognosis
86. 2-microglobulin, immunoglobulin A and erythrocyte sedimentation rate
87. 2-microglobulin and prediction of progresion to AIDS in HIV-infected injection drug users
88. Rate of CD4 decline and neuropsychological performance in HIV infection
89. HIV related neuropsychological impairment and immunodeficiency. CD8+ lymphocytes and neopterin are related to HIV-encephalopathy
90. Human immunodeficiency virus (HIV): Immune system compromise and neuropsychological functioning
91. Neuropsychological function in physically asymptomatic, HIV-seropositive men
92. Neuropsychologic functioning of human immunodeficiency virus-infected children with hemophilia
93. Effects of immunosuppression and disease severity upon neuropsychological function in HIV infection
94. Immune function and neuropsychological performance in HIV-1-infected homosexual men
95. A controlled study of early neurologic abnormalities in men with asymptomatic human immunodeficiency virus infection
96. Neuropsychological performance and CD4 levels in HIV-1 asymptomatic infection
97. Cognitive impairment in asymptomatic stoges of HIV infection. A longitudinal study
98. Marcadores séricos e inmunológicos de progresión a síndrome de inmunodeficiencia adquirida en hemofílicos
99. 2-microglobulin as prognostic indices in human immunodeficiency virus type 1 infection
100. 2-microglobulin and neopterin
101. 2-microglobulin in patients with AIDS dementia complex: An expanded series including response to zidovudine treatment
102. CFS follow-up in HIV-1 infection: Intrathecal production of HIV-specific and unspecific IGG, and beta-2-microglobulin increase with duration of HIV-1 infection
103. Cerebrospinal fluid human immunodeficiency virus tipe 1 (HIV-1) P24 antigen levels in HIV-1-related dementia
104. 2-microglobulin in HIV-1 dementia
105. 2 microglobulin and CD4 counts to neuropsychological performance in HIV-1-infected intravenous drug users
106. Serum beta-2-microglobulin levels increases in HIV-infection: Relation to seroconversion, cd4 T-cell fall and prognosis
107. Immunological and virological markers of disease progresion
108. Serum β2-microglobulin and prediction of progresion to AIDS in HIV infection
109. Relationships among cerebrospinal fluid human immunodeficiency virus tipe 1 (HIV-1) culture, quinolinic acid level and reaction time in HIV-1-infected individuals
110. Measuring HIV-1 RNA and interferon-alpha in the cerebrospinal fluid of AIDS patients: Insights into the pathogenesis of AIDS dementia complex
111. Relationship between human immunodeficiency virus-associated dementia and viral load in cerebrospinal fluid and brain
112. CSF, plasma viral load and HIV associated dementia
113. Sustained cognitive decline in HIV infection: Relationship to CD4+ cell count, plasma viremia and P24 antigenemia
114. Improvement of motor performance of HIV-positive patients under AZT therapy
115. Long-term zidovudine reduces neurocognitive deficits in HIV-1 infection
116. Influence of risk group and zidovudine therapy on the development of HIV encephalitis and cognitive impairment in AIDS patients
117. Nimodipine plus zidovudine versus zidovudine alone in the treatment of HIV-1-associated cognitive deficits
118. Factors associated with neuropsychological performance in HIV-seropositive subjects without AIDS
119. Presentation and course of AIDS dementia complex: 10 years of follow-up in Amsterdam, the Netherlands
120. Neurological outcomes in late HIV infection: Adverse impact of neurological impairment on survival and protective effect of antiviral therapy. AIDS clinical trial group and neurological AIDS research consortium study team
121. Effects of zidovudine in 30 patients with mild to end-stage AIDS dementia complex
122. Anti-HIV drug therapy
123. The efficacy of azidothymidone (AZT) in the treatment of patients with AIDS and AIDS-related complex. A double-blind, placebo-controlled trial
124. Neuropsychological outcome of zidovudine (AZT) treatment of patients with AIDS and AIDS-related complex
125. Response of human immunodeficiency virus associated neurological disease to 3′-azido-3′-deoxythymidine
126. Changing incidence of HIV-induced brain lesions in Oslo, 1983-1994: Effects of zidovudine treatment
127. Declining incidence of AIDS dementia complex after introduction of zidovudine treatment
128. Neuropsychological evaluation of zidovudine in asymptomatic HIV-1 infection: A longitudinal placebo-controlled study
129. Neuropathological evidence that zidovudine reduces incidence of HIV infection of brain
130. Zidovudine therapy and HIV encephalitis: A 10-year neuropathological survey
131. Reduces frecuency of HIV-induced brain lesions in AIDS patients treated with zidovudine
132. Brain growth and cognitive improvement in children with human immunodeficiency virus- induced encephalopathy after 6 months of continuous infusion zidovudine therapy
133. Neuroimaging in HIV infection: Neuropsychological and pathological correlation
134. Reversal of brain metabolic abnormalities following treatment of AIDS dementia complex with 3′-azido-2′, 3′-dideoxythymidine: A PET-FDG study
135. Zidovudine treatment of the AIDS dementia complex: Results of a placebo-controlled trial
136. Effect of combination therapy with zidovudine and didanasine on neuropsychological functioning in patients with simptomatic HIV disease: A comparision of simultaneous and alternating regimens
137. Zidovudine reduces intrathecal immunoactivation in patients with early human immunodeficiency virus type 1 infection
138. The Edinburgh cohort of HIV-positive infecting drug users at 10 years after infection: A case-control study of the evolution of dementia
139. The effect of zidovudine on neuropsychiatric measures in HIV-infected men
140. Pharmacatherapy of HIV dementia
141. Only temporary improvement in impaired neuropsychological function in AIDS patients treated with zidovudine
142. Long-term effects of high-dose zidovudine treatment on neuropsychological performance in midly symptomatic HIV-positive patients: Results of a randomized, double-blind, placebo-controlled investigation
143. Pilot study of the efficacy of atevirdine in the treatment of AIDS dementia complex
144. The use of methylphenidate for cognitive decline associated with HIV disease
145. Combination antiretroviral therapy improves psychomotor speed performance in HIV-seropositive homosexual men. Multicenter AIDS cohort study (MACS)
146. Positive and sustained effects of highly active antiretroviral therapy on HIV-1-associated neurocognitive impairment
147. Sustained - Release methylphenidate for cognitive impairment in HIV-1-infected drug abusers: A pilot study
148. Long term toxicity/activity profile of 2′, 3′-dideoxyinosine in AIDS or AIDS-related complex
149. AIDS dementia complex and didanosine